title: Expect the unexpected: primary breast MALT lymphoma.
authors.forename: Daniela
authors.initials: D
authors.lastname: Ghetu
authors.forename: Véronique
authors.initials: V
authors.lastname: Membrez
authors.forename: Amade
authors.initials: A
authors.lastname: Bregy
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Vees
authors.forename: Denis
authors.initials: D
authors.lastname: Hottelier
authors.forename: Christophe
authors.initials: C
authors.lastname: Girardet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Schneider
authors.forename: Sabine
authors.initials: S
authors.lastname: Bieri
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis* / Q000188:drug therapy / Q000532:radiotherapy; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone